Table 2.
Detection of CSCs in established lung cancer cell lines.
| Cell line | Percentage | Method | Reference |
|---|---|---|---|
| LHK2, 1-87, A549, Lc817 | 0.4% to 2.8% | SP | [23] |
| A549 | 0.98% | CD133 | [24] |
| H446 | 1% | CD133 | [24] |
| A549 | >45% | Cloning and tumorigenic analyses | [25] |
| H446 | >45% | Cloning and tumorigenic analyses | [25] |
| A549 | 24% | SP | [26] |
| H460, H23, HTB-58, A549, H441, and H2170 | 1.5% to 6.1% | SP | [27] |
| NCI-H82, H146, H526, A549, and H460 | 0.8% to 1% | SP | [28] |
| H446 | 6.3 ± 0.1 | SP | [29] |
| NSCLC cell lines H460, H125, H322, H358 | average of 2% (2.16 ± 1.28) | Aldefluor followed by clonogenic assays | [30] |
| A549, H1299, CCL-1, CCL-5, C299 | 0.3% to 1% | CD133+ follow serum free culture | [31] |
| 60 primary tissue samples | 0.02% to a maximum of 35% | CD133+ESA+ | [32] |